FRX.TO

Companies
Toronto Stock Exchange
Fennec Pharmaceuticals Inc.
Health Care
Price Chart
Overview

About FRX.TO

fennec pharmaceuticals inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the united states. its lead product pedmark, a formulation of sodium thiosulfate, which has completed the phase iii clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. the company was formerly known as adherex technologies inc. and changed its name to fennec pharmaceuticals inc. in september 2014. fennec pharmaceuticals inc. was founded in 1996 and is based in research triangle park, north carolina.

Market Cap
$260.7M
Volume
5.0K
Avg. Volume
2.3K
P/E Ratio
10.695187165775401
Dividend Yield
0.00%
Employees
30.0

Company Information

Exchange
Toronto Stock Exchange
Sector
Health Care
Industry
Biotechnology
Latest News for FRX.TO
Risk & Correlation Analysis
Market Correlation
0.48
Low Correlation
Volatility
High (0.65)
Relative to market

Macro Factor Sensitivities

Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for FRX.TO.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, FRX.TO shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$260.7M
Volume5.0K
P/E Ratio10.70
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 29, 2023
Related Securities

PortfolioPilot Analysis

Get AI-powered insights on how FRX.TO fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025